Fernando Torres, M.D.
Medical Director of Lung Transplantation; Head of the Pulmonary Hypertension Program
Department Internal Medicine
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.View Clinical Profile
Fernando Torres, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He is also the Medical Director of Lung Transplantation and Head of the Pulmonary Hypertension Program in the Division of Pulmonary and Critical Care Medicine.
Originally from Puerto Rico, Dr. Torres holds a bachelor's degree in biology and chemistry from Cornell University in Ithaca, New York. He also received his medical degree from Cornell University. He completed internal medicine residency training at UT Southwestern Medical Center. He then completed advanced training through a fellowship in pulmonary disease and critical medicine with a focus on lung transplant and lung volume reduction at the Anschutz Medical Campus at the University of Colorado Denver.
Certified by the American Board of Internal Medicine in pulmonary disease and critical care medicine, Dr. Torres joined the UT Southwestern faculty in 2000.
Dr. Torres' research interests include infections in lung transplant patients, cardiopulmonary disorders, and pulmonary arterial hypertension. He has been the Principal Investigator on several studies and his investigations have resulted in numerous publications in peer-reviewed and non-peer-reviewed journals. Additionally, he has presented his findings at scientific conferences throughout the United States and around the world.
At UT Southwestern, Dr. Torres is involved in several committees. These include the Revenue Cycle Committee, the Professional Affairs and Ethics Committee, the Solid Organ Transplant Programs Steering Committee, and the Transplant Advisory Committee.
Dr. Torres is active in several professional societies, including the Texas Medical Association, and the International Society for Heart & Lung Transplantation Lung Transplant and Pulmonary Hypertension Councils. He is currently the Associate Editor of Advances in Pulmonary Hypertension.
Outside of medicine, Dr. Torres is a member of the Mid-Cities Stamp Club.
- Medical School
- Weill Cornell Medical College (1994)
- UT Southwestern Medical Center (1995), Internal Medicine
- UT Southwestern Medical Center (1997), Internal Medicine
- University of Colorado Health Sciences Center (2000), Pulmonary Diseases & Critical Care Medicine
- Lung Transplantation
- Pulmonary Hypertension
- Treprostinil for the treatment of pulmonary arterial hypertension.
- Torres F, Rubin LJ Expert Rev Cardiovasc Ther 2013 Jan 11 1 13-25
- HLA mismatches influence lung transplant recipient survival, bronchiolitis obliterans and rejection: implications for donor lung allocation.
- Peltz M, Edwards LB, Jessen ME, Torres F, Meyer DM J. Heart Lung Transplant. 2011 Apr 30 4 426-34
- Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension.
- Torres F Int. J. Clin. Pract. 2007 Oct 61 10 1756-65
- Endothelian Receptor Antagonists in Pulmonary Hyertension. Business Briefing
- F. Torres US Respiratory Care 2006 77-82
- Routine computed tomography screening of the chest in high-risk cardiac transplant recipients may improve survival.
- Rosenbaum DH, Bhojani RA, Dikmen E, Kaiser PA, Paul MC, Wait MA, Meyer DM, Jessen ME, Yancy CW, Rosenblatt RL, Torres F, Perkins S, Ring WS, DiMaio JM J. Heart Lung Transplant. 2005 Dec 24 12 2043-7
- Monthly infusion of cytomegalovirus immune globulin (CMVIG) decreases the incidence of bacterial and fungal infections in the first year following lung transplantation.
- Zamora MR, Torres F, Marquesan J, Diercks M, Hodges T J. Heart Lung Transplant. 2001 Feb 20 2 200
- Community acquired respiratory viruses in lung transplant patients: incidence and outcomes.
- Hodges TN, Torres FP, Marqueson J, Diercks M, Zamora MR J. Heart Lung Transplant. 2001 Feb 20 2 169-170
- Both cell surface and internalized beta-adrenoceptors are reduced in the failing myocardium.
- Sullebarger JT, Fan TH, Torres F, Liang CS Eur. J. Pharmacol. 1991 Nov 205 2 165-9
- Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy Results from a Phase 2 randomized, parallel group, placebo-controlled trial.
- Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, Klassen P, Shanahan W, Grundy J, Hoffmann I, Cabell C, Escribano Subías P, Sood N, Keogh A, D'Souza G, Rubin L, Eur. Respir. J. 2019 Aug
- Incidence and variables associated with 30-day mortality after lung transplantation.
- Banga A, Mohanka M, Mullins J, Bollineni S, Kaza V, Huffman L, Peltz M, Bajona P, Wait M, Torres F Clin Transplant 2019 Feb 33 2 e13468
Honors & Awards
- Cornell University - 1990
Graduated with distinction in all subjects (1990)
- Golden Key National Honor Society
- C.H. Ferguson Scholarship
- Incentive for Excellence
Scholarship Prize from NSF: Physics-1988, Chemistry-1989 (1988)
- American College of Physicians
- American Medical Association
- American Thoracic Society for Heart & Lung Transplantation
- Pulmonary Hypertension Association
- Texas Medical Association